Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer

This publication has 16 references indexed in Scilit:

• A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma
  European Journal of Cancer and Clinical Oncology, 1985
• RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA
  The Lancet, 1984
• Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation)
  American Journal of Obstetrics and Gynecology, 1983
• A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer
  Gynecologic Oncology, 1983
• A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma
  Cancer, 1983
• Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
  Cancer Chemotherapy and Pharmacology, 1982
• Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)
  Cancer, 1981
• Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin
  Cancer, 1981
• Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin
  Cancer, 1980
• Cisplatin (cis-diamminedichloroplatinum II)
  Cancer Treatment Reviews, 1979